Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Depreciation and Depletion (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Depreciation and Depletion for 6 consecutive years, with $212000.0 as the latest value for Q4 2018.

  • Quarterly Depreciation and Depletion rose 140.91% to $212000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2018, up 202.62% year-over-year, with the annual reading at $1.5 million for FY2025, 13.21% up from the prior year.
  • Depreciation and Depletion hit $212000.0 in Q4 2018 for Armata Pharmaceuticals, down from $336000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $401000.0 in Q2 2018 to a low of -$27000.0 in Q3 2014.
  • Historically, Depreciation and Depletion has averaged $107250.0 across 5 years, with a median of $85000.0 in 2016.
  • Biggest five-year swings in Depreciation and Depletion: crashed 228.57% in 2014 and later surged 470.37% in 2015.
  • Year by year, Depreciation and Depletion stood at $68000.0 in 2014, then increased by 20.59% to $82000.0 in 2015, then rose by 13.41% to $93000.0 in 2016, then decreased by 5.38% to $88000.0 in 2017, then skyrocketed by 140.91% to $212000.0 in 2018.
  • Business Quant data shows Depreciation and Depletion for ARMP at $212000.0 in Q4 2018, $336000.0 in Q3 2018, and $401000.0 in Q2 2018.